Bevacizumab or Avastin, a drug used for treating bowel cancer that is extensively been employed off-label for preventing AMD (wet age related macular degeneration), has been found to be risk-free , effectual and a comparatively low-priced substitute to accepted medication ranibizumab or Lucentis. Presently, numerous large-scaled on-going studies are being conducted for evaluating the duo drugs.
Lucentis was not part of this trial since it had not garnered the license for usage when the study commenced, outcomes of which are printed in the British Medical Journal. The study investigators back bevacizumab to be instantly implemented in heath care systems that have restricted budget criteria which avert inaccessibility to ranibizumab among several patients.
In majority of the nations globally that have no therapy or substandard treatments for wet age related macular degeneration patients, the apt usage of vastly low priced bevacizumab would have a positive and unswerving effect in lowering episode sightlessness due to this eye condition, the study researchers have mentioned.
Wet age related macular degeneration is the prevailing reason for eye sight failure or virtual sightlessness among elderly individuals above fifty years of age in N. America and several European countries. Eye sight failure is the consequence of advancing loss of light-sensitive cells present at the rear of the eye occurring due to harm from irregular, leaky blood vessels. Those who suffer from this condition do not suffer from blindness; however experience immense difficulty while reading or driving or undertaking chores which need fineness, sharpness and core vision.
During 2006, researchers from 3 eye centers in the United Kingdom came to the decision to ascertain if bevacizumab is an effectual and risk-free therapy for wet age related macular degeneration in comparison to benchmark National Health Service care obtainable during present times.
During the course of the study, 131 entrants who were in the age of fifty years or above, all having wet age related macular degeneration were arbitrarily allotted to be administered bevacizumab shots at 6 weekly time intervals or benchmark care from 1 of the three diverse therapies obtainable on the National Health Service or NHS at the onset of the trial. Measurement of visual acuteness was done at the onset of the trial (base-line) and then monitoring was done over a time period of a year (or fifty-four weeks).
Subsequent to a year’s time:
- Thirty-two percent of patient set who were administered bevacizumab were observed to gain fifteen or fifteen plus letters of visual acuity from baseline.
- Three percent of the patients from the benchmark care set were noted to gain fifteen or more letter types of visual acuity from baseline.
- Ninety-one percent of patients given bevacizumab therapy were found to lose lesser than fifteen letters from baseline visual acuity.
- Sixty-seven percent patients from the benchmark care set were observed to lose lesser than fifteen letters from baseline visual acuity.
